What are ASCO recommendations for stage IV non–small cell lung cancer (NSCLC) receiving carboplatin plus paclitaxel?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

For patients receiving carboplatin plus paclitaxel, the guidelines recommend adding bevacizumab, 15 mg/kg once every 3 weeks, and continuing it as tolerated until disease progression, Exceptions include patients with any of the following:

  • Squamous cell carcinoma (SCC) histologic type
  • Clinically significant hemoptysis
  • Inadequate organ function
  • ECOG PS >1
  • Clinically significant cardiovascular disease
  • Medically uncontrolled hypertension

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!